{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk;", "lead_paragraph": "A vaccine to prevent tuberculosis that is used only infrequently in this country, largely because Federal health officials consider it unreliable, is surprisingly effective, a new statistical study has discovered. It was found to reduce the risk of full-fledged tuberculosis of the lung by 50 percent and death by 71 percent. The vaccine known as BCG, for bacillus Calmette-Guerin, after the French scientists who began developing it in 1906, is reported to be the most widely used vaccine in the world. It has been injected into an estimated three billion people, and the World Health Organization recommends BCG as a standard childhood immunization.", "headline": {"main": "Tuberculosis Vaccine Found Surprisingly Effective in Study"}, "abstract": null, "print_page": "14", "word_count": 1314, "_id": "4fd1bd6e8eb7c8105d6ea3fb", "snippet": "A vaccine to prevent tuberculosis that is used only infrequently in this country, largely because Federal health officials consider it unreliable, is surprisingly effective, a new statistical study has discovered. It was found to reduce the risk of...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1994/03/02/us/tuberculosis-vaccine-found-surprisingly-effective-in-study.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "HEALTH PAGE (NYT)"}, {"name": "subject", "value": "VACCINATION AND IMMUNIZATION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TUBERCULOSIS"}], "byline": {"person": [{"firstname": "Lawrence", "middlename": "K.", "lastname": "ALTMAN", "rank": 1, "role": "reported", "organization": ""}], "original": "By LAWRENCE K. ALTMAN"}, "document_type": "article", "pub_date": "1994-03-02T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk;", "lead_paragraph": "An experimental new drug appears to be the first to slow the fatal progression of Lou Gehrig's disease, the illness that until now has defied all attempts at treatment. The medicine, called riluzole, is not a cure. But a study financed by the maker of riluzole found it seemed to delay crippling symptoms and death. \"Survival almost doubled in some patients,\" said Dr. Jeffrey Rothstein of Johns Hopkins University, co-director of another, larger study of the treatment. \"That's just unheard of.\" He described riluzole as \"a big, big step.\" But some experts are skeptical and worry that the initial study's seemingly positive findings could have been a statistical fluke.", "headline": {"main": "Drug Reported to Slow Lou Gehrig's Disease"}, "abstract": null, "print_page": "14", "word_count": 680, "_id": "4fd1bf9b8eb7c8105d6ed885", "snippet": "An experimental new drug appears to be the first to slow the fatal progression of Lou Gehrig's disease, the illness that until now has defied all attempts at treatment. The medicine, called riluzole, is not a cure. But a study financed by the maker...", "source": "AP", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1994/03/02/us/drug-reported-to-slow-lou-gehrig-s-disease.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "HEALTH PAGE (NYT)"}, {"name": "organizations", "value": "RHONE-POULENC RORER"}, {"name": "subject", "value": "AMYOTROPHIC LATERAL SCLEROSIS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "RILUZOLE (DRUG)"}], "byline": null, "document_type": "article", "pub_date": "1994-03-02T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 2, "offset": 0, "time": 38}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}